Sources Novo Nordisk NDA filing for CagriSema, December 18, 2025 American Diabetes Association REDEFINE-1 and REDEFINE-2 results, ADA 2026 Scientific Sessions HCPLive REDEFINE-1 Phase 3 safety and efficacy data Clinical Trials Arena REDEFINE-4: CagriSema vs tirzepatide head-to-head, February 2026 Life Science Daily News CagriSema FDA review timeline and NDA update, July 2026 PharmExec REDEFINE-1 results: CagriSema falls short of 25% weight loss target Drugs.com CagriSema FDA approval status history New England Journal of Medicine REDEFINE-1 full publication (presented at ADA 2026) Novo Nordisk REIMAGINE Phase 3 diabetes trial results, ADA 2026 and The Lancet FDA Wegovy (semaglutide) prescribing information, 2025 Related reading on Heally: What is Wegovy HD
Corticosteroid injections may actually impair long-term tendon health despite providing short-term pain relief
For post-surgical recovery, systemic inflammation, or injuries in multiple spots, go with TB-500 first, or combine both if your budget allows
Documented anti-doping rule violations have occurred based on non-analytical findings through information gathering
doses over ~1 mg/day are not associated with added benefit
Your kidneys work 24/7 to keep the body healthy by filtering out toxins and extra fluid and regulating blood pressure